Novartis radioligand therapy Lutathera® FDA approved as
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17)...
Source: globenewswire.com
Page 2 - Developmental Therapeutics Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Developmental Therapeutics Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Developmental Therapeutics Program Today - Breaking & Trending Today
FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
Source: pharmacytimes.com
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and...
Source: prnewswire.com
Doctors Weigh Patient Goals Instead of 'Dictating' Melanoma Treatment
An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.
Source: curetoday.com
Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate Cancer
Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.
Source: onclive.com